10-K: Profusa, Inc. Reports 2025 Financials Amid Nasdaq Delisting Concerns

Profusa, Inc. filed its annual report detailing 2025 financial performance, ongoing product development for biosensors, and significant challenges including Nasdaq listing compliance.

Summary

• Profusa, Inc. (formerly NorthView Acquisition Corp.) filed its annual report for the fiscal year ended December 31, 2025.
• The company reported a net loss of $35.8 million for 2025, an increase from $9.2 million in 2024, with significant increases in general and administrative expenses due to transaction closing costs and personnel expenses.
• Profusa is developing biosensing platforms, Lumee Oxygen for wound care and Lumee Glucose for diabetes management, with CE approval for Lumee Oxygen in Europe and plans for U.S. FDA approval.
• The company received notices from Nasdaq regarding non-compliance with minimum bid price and market value of listed securities requirements and is appealing a potential delisting.
• Profusa has a history of net losses and has raised capital through various debt and equity instruments, with substantial doubt about its ability to continue as a going concern.
• The company is also subject to ongoing regulatory scrutiny and potential product liability risks.
• Subsequent to year-end, Profusa entered into a letter of intent to acquire assets from Bio Insights LLC for $30 million in equity.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss, operational challenges including Nasdaq delisting concerns, and the going concern warning, despite ongoing product development and funding efforts.

Positives

• Profusa received CE Mark approval for its Lumee Oxygen platform in Europe.
• The company is actively pursuing U.S. FDA approval for Lumee Oxygen and Lumee Glucose.
• Profusa has a strong intellectual property portfolio with 25 issued U.S. patents and 32 rest-of-world patents.
• The company has secured significant funding through various equity and debt instruments, including $10.3 million from an ELOC and $11.0 million from PIPE investments in 2025.
• Profusa entered into a know-how license agreement with Mayo Foundation for Medical Education and Research to advance its technology.
• The company's PPP loan of $1.3 million was approved for forgiveness in February 2026.

Negatives

• Profusa reported a net loss of $35.8 million for the year ended December 31, 2025, compared to $9.2 million in 2024.
• General and administrative expenses increased significantly by 732% to $24.9 million in 2025, largely due to transaction closing costs ($14.5 million).
• The company has a history of net losses and accumulated deficit of $160.8 million as of December 31, 2025.
• Profusa has received notices from Nasdaq for failing to meet continued listing requirements and is subject to potential delisting.
• The company has substantial doubt about its ability to continue as a going concern.
• Profusa has identified material weaknesses in its internal control over financial reporting.
• The company's ability to commercialize its products is dependent on obtaining regulatory approvals, which is not guaranteed.
• The company has outstanding debt and related party obligations, with some notes in default.
• The company sold its Bitcoin holdings due to current market conditions and capital allocation priorities.

Risks

• The company faces substantial doubt about its ability to continue as a going concern.
• Profusa has a limited operating history and has incurred significant losses since inception, with expectations of continued losses.
• The company is at risk of delisting from the Nasdaq Global Market due to failure to meet continued listing requirements.
• Failure to obtain additional funding on acceptable terms could force the company to delay, limit, or terminate product commercialization or development efforts.
• Profusa operates in a highly competitive market and may not be able to compete effectively against larger, well-established companies.
• Research and development efforts may not result in commercially viable products or significant future revenues.
• The company is subject to risks associated with international operations, including currency fluctuations and differing regulatory environments.
• Consumer confusion about product features could lead to the purchase of competitive products.
• The commercialization of Lumee Oxygen is expected to generate nearly all revenue until additional products are approved, creating significant reliance on this single product.
• Dependence on third-party suppliers makes Profusa vulnerable to supply disruptions, suboptimal quality, noncompliance, and price fluctuations.
• The size and growth of the addressable market may be smaller than estimated.
• There is no guarantee that the FDA will grant 510(k) clearance or PMA approval for its products.
• Failure to comply with applicable laws and government regulations in the heavily regulated healthcare industry could result in penalties.
• The discovery of serious safety issues with products or a product recall could negatively impact the company.
• Changes in healthcare policy and reform legislation could materially affect the business.
• The company is subject to complex and evolving privacy, data protection, and security laws.
• Inability to adequately protect intellectual property could allow competitors to produce products based on Profusa's technology.
• Material weaknesses in internal control over financial reporting could adversely affect the ability to report financial information accurately.
• Cybersecurity risks and cyber incidents could compromise confidential data or critical systems.

Future Outlook

Profusa expects to continue incurring substantial losses in the foreseeable future as it invests in product development, clinical trials, and commercialization efforts. The company anticipates needing additional financing to fund operations and growth, and its ability to achieve profitability is dependent on successful commercialization of its products and obtaining regulatory approvals.

Management Comments

• "Our consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business."
• "As of December 31, 2025, there continues to be factors which raise substantial doubt about our ability to continue as a going concern within one year from the date the consolidated financial statements are issued."
• "We expect to incur additional annual expenses as a public company for, among other things, directors and officers liability insurance, director fees, and additional internal and external accounting, legal and administrative resources."
• "We have been notified by Nasdaq of our failure to comply with certain Nasdaq Global Market continued listing requirements and if we are unable to regain compliance with all applicable continued listing requirements and standards of the Nasdaq Global Market, our Common Stock could be delisted from the Nasdaq Global Market."

Industry Context

StockSavvy.ai notes that Profusa operates in the highly competitive digital health and medical technology sector, focusing on biosensing solutions. The company's strategy of developing innovative platforms like Lumee Oxygen and Lumee Glucose positions it within the growing markets for wound care and diabetes management. However, the path to commercialization is heavily reliant on regulatory approvals (FDA) and market adoption, facing significant competition from established players. The company's financial performance and Nasdaq listing status highlight the inherent risks and capital intensity of this industry.

Comparison to Industry Standards

• Profusa's Lumee Oxygen platform aims to provide real-time tissue oxygen monitoring, a capability that competes with existing transcutaneous oximetry (TCPO2) devices from companies like Perimed AB and Radiometer Medical.
• In the continuous glucose monitoring (CGM) market, Lumee Glucose will compete with established players such as Dexcom, Abbott (Freestyle Libre), and Medtronic (Guardian Connect), which currently dominate the market for Type 1 and Type 2 diabetes patients.
• Profusa's sensor technology, designed for longer functionality (up to 6-9 months) and simpler injection via hypodermic needle, aims to differentiate itself from current CGM sensors that typically last 7-14 days and may require more invasive implantation or have shorter lifespans.
• The company's approach to data generation and its potential integration with telemedicine and health/wellness coaching platforms aligns with broader industry trends towards data-driven healthcare solutions, a space expected to reach nearly $400 billion by 2028.

Corporate Governance

Legal Proceedings

• The company accrued approximately $0.1 million related to a vendor litigation for breach of contract, with a judgment entered in favor of the vendor.
• A former employee has made a demand for unpaid wages of approximately $0.2 million, including statutory penalties, with potential litigation if not resolved.

Related Party Transactions

• Profusa has outstanding convertible notes and promissory notes with related parties, including Tasly and NVAC Sponsor I, LLC.
• The company has a convertible promissory note with NVAC Sponsor I, LLC, which was amended multiple times and is currently in default.
• The company has outstanding convertible notes with Tasly, which are also in default and have been valued at fair value.

Stakeholder Impact

• Shareholders may experience dilution due to future equity issuances and potential conversion of debt instruments.
• The risk of delisting from Nasdaq could negatively impact the marketability and liquidity of the company's common stock.
• Creditors and noteholders face risks related to the company's going concern status and potential defaults on debt obligations.
• Employees may be affected by the company's financial performance and potential restructuring or operational changes.
• Customers and partners may be impacted by potential supply chain disruptions or delays in product development and commercialization.

Next Steps

• Regain compliance with Nasdaq continued listing requirements.
• Obtain U.S. FDA approval for Lumee Oxygen and Lumee Glucose.
• Initiate commercialization efforts for Lumee Oxygen in Europe in early 2026.
• Continue discussions with investors for potential joint ventures in Asia Pacific markets.
• Execute definitive agreements for the proposed acquisition of assets from Bio Insights LLC.
• Remediate material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

While Profusa is developing innovative biosensing technology with potential in large markets, the significant financial losses, going concern issues, and Nasdaq delisting risk warrant a cautious approach. The company's ability to secure regulatory approvals and navigate its financial challenges will be critical. A 'hold' recommendation reflects the speculative nature of the investment given the current headwinds, but acknowledges the long-term potential if these hurdles are overcome.

Keywords

Profusa, 10-K, Annual Report, Biosensor, Lumee Oxygen, Lumee Glucose, Continuous Glucose Monitoring, Digital Health, Medical Technology, FDA Approval, Nasdaq Listing, Going Concern, Financial Results, Biotechnology